Publications

  1. Stein, C.A. and Morton, T.H. "Methyllithium undergoes halogen exchange faster than it abstracts a carboxylic proton: Stereoselective reduction of 1-methyl-2,2-dibromocyclopropanecarboxylic acid", Tetrahedron Letters, 1973, (49) 4933-4936.
  2. Stein, C.A., Bouma, S., Carlson, J., Cornelius, C., Maeda, J., Weschler, C., Deutsch, E., and Hodgson, K. "Structural characterization and resulting implications for the mechanism of formation of Bis(2-mercaptoethylamine)ethylenediammine chromium(III) perchlorate, [(en)Cr(SCH2CH2NH2)2] ClO4 ", Inorganic Chemistry, 1975, (15) 1183-1186.
  3. Stein, C.A., Ellis, P.E., Elder, R.C., and Deutsch, E. "Synthesis and characterization of cobalt (III) complexes containing a coordinated selenol.  A structural trans effect in (2-selenolatoethylamine-N,Se) bis(ethylenediammine)cobalt(III) nitrate", Inorganic Chemistry, 1976, (15) 1618-1623.
  4. Stein, C.A. and Taube, H. "Trimethylsulfonium ion as a ligand: Synthesis and characterization of [(NH3)5RuS(CH3)3](PF6)3 , J. Amer. Chem. Soc., 1978, (100) 336.
  5. Stein, C.A. and Taube, H. "Manifestations of sulfur to sulfur through-space interactions in complex ion spectra", J. Amer. Chem. Soc., 1978, (100), 1635-1637.
  6. Stein, C.A. and Taube, H. "Pentaamineruthenium dimethyl chalcogenide complexes", Inorganic Chemistry, 1979, (18) 1168-1170.
  7. Stein, C.A. and Taube, H. "Ruthenium ammine disulfides", Inorganic Chemistry, 1979, (18) 2212-2216.
  8. Stein, C.A. and Taube, H. "Manifestations of sulfur to sulfur through-bond interactions in complex ion spectra, J. Amer. Chem. Soc., 1981, (103) 693-695.
  9. Stein, C.A., Lewis, N., and Seitz, G. "Long-range intervalence electron tunneling through fully saturated systems", J. Amer. Chem. Soc., 1982, (104) 2596-2599.
  10. Stein, C.A., Lewis, N.A., Seitz, G. and Baker, A.D. "Photoelectron spectra of dithiaspirocyclobutane molecules.  Electronic spectra of their ruthenium complexes and evidence from CNDO/2 calculations for a hyperconjugating electron-transfer mechanism", Inorganic Chemistry, 1983, (22) 1124-1128.
  11. Stein, C.A., Ernst, J., Stern, M., Daley, T. and Caspe, W. "Thoracic actinomycosis in a recent tuberculin converter", Pediatric Infectious Disease, 1983, (2) 52-55.
  12. Baker, A.D., Scharfman, R. and Stein, C.A. "Ultra long-range through-bond interactions in dithiaspirane disulfoxides as revealed by photoelectron spectroscopy", Tetrahedron Letters, 1983, (24) 2957-2960.
  13. Lalezari, I., and Stein, C.A. "A simple one-step synthesis of 3-amino-2,4(1H,3H)quinazolindiones", J. Heterocyclic Chem., 1984, (21) 5-7.
  14. Stein, C.A., Baker, A.D., Lewis, N.A. and White, P.S. "Evidence for through-space interactions between sulfur and nitrogen lone pairs in 2, 2a, 4, 4a, 6, 6a-hexahydro-1,3,5-trithia-7-azacyclopenta[cd]-pentalene", J. Chem. Soc. Dalton Transactions, 1984, 2073-2075.
  15. Stein, C.A., Saville, W., Yarchoan, R., Broder, S. and Gelmann, E., "Suramin and function of the adrenal cortex", Ann. Intern. Med., 1986, (104), 286-287.
  16. Feuillan, P., Raffeld, M., Stein, C.A., Lipford, N., Rehnquist, D., Myers, C.E., LaRocca, R.V. and Chrousos, G.P. "Effects of suramin on the function and structure of the adrenal cortex in the cynomolgus monkey", J. Clin. Endocrinol. Metab., 1987, (65) 153-160
  17. Holland, E., Stein, C.A., Palestine, A., La Rocca, R., Chan, C.-C., Kuwabara, T., Myers, C., Thomas, R. McAtee, N. and Nussenblatt, R. "Suramin keratopathy", Am. J. Ophthalmology, 1988, (106) 216-221.
  18. Stein, C.A., Subasinghe, C., Shinozuka, K. and Cohen, J. "Physicochemical properties of phosphorothioate oligodeoxynucleotides", Nucl. Acids Res., 1988, (16) 3209-3221.
  19. Horne, M., Stein, C.A., La Rocca, R. and Myers, C. "Circulating glycosaminoglycan anticoagulants associated with suramin treatment", Blood, 1988, (71) 273-279.
  20. Stein, C.A., Mori, K., Loke, S.L., Subasinghe, C., Shinozuka, K., Cohen, J.S. and Neckers, L.M. "Phosphorothioate and normal oligodeoxynucleotides with 5'-linked acridine:  characterization and preliminary kinetics of cellular uptake",  Gene, 1988, (72) 333-341.
  21. Loke, S., Stein, C.A., Zhang, X., Avigan, M., Cohen, J. and Neckers, L. "Delivery of c-myc  antisense phosphorothioate oligodeoxynucleotides to hematopoetic cells in culture by liposome fusion:  Specific reduction in c-myc  protein expression correlates with inhibition of cell growth and DNA synthesis",  Curr. Top. Microbiol. Immunobiol., 1988, (141) 282-289.
  22. Matsukura, M., Zon, G., Shinozuka, K., Stein, C., Mitsuya, H., Cohen, J. and Broder, S. "Synthesis of phosphorothioate analogues of oligodeoxynucleotides and their antiviral activity against human immunodeficiency virus (HIV)",  Gene, 1988, (72), 343-347.
  23. Yano, T., Linehan, M., Anglard, P., Lerman, M., Daniel, L.N., Stein, C.A., Robertson, C.N., LaRoca, R., and Zbar, B. "Genetic changes in human adrenocortical carcinomas", J. Natl. Cancer Inst., 1989, (81) 518-523.
  24. Stein, C.A., LaRocca, R., Thomas, R., McAtee, N., and Myers, C.E. "Suramin: An anticancer drug with a unique mechanism of action", J. Clin. Oncology, 1989, (7) 499-508.
  25. Loke, S.L., Stein, C., Zhang, X., Mori, K., Nakanishi, M., Subasinghe, C., Cohen, J.S., and Neckers, L.M. "Characterization of oligodeoxynucleotide transport into living cells ",  Proc. Natl. Acad. Sci. USA., 1989, (86) 3474-3478.
  26. Majumdar, C., Stein, C.A., Cohen, J.S., Broder, S. and Wilson, S. "Stepwise mechanism of HIV reverse transcriptase: Primer function of phosphorothioate oligodeoxynucleotide", Biochemistry, 1989, (28) 1340-1346.
  27. Matsukura, M., Zon, G., Shinozuka, K., Robert-Guroff, M., Shimada, T., Stein, C.A., Mitsuya, H., Wong-Staal, F., Cohen, J. and Broder, S. "Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells",  Proc. Natl. Acad. Sci. USA, 1989, (86) 4244-4249.
  28. Gao, W., Stein, C.A., Cohen, J., Dutschman, G. and Cheng, Y.-C. "Effect of phosphorothioate homo-oligodeoxynucleotides on herpes simplex virus type 2-induced DNA polymerase," Biochemistry, 1989, (264) 11521-11526.
  29. Mori, K., Subasinghe, C., Stein, C.A., and Cohen, J. "Synthesis and properties of novel 5'-linked oligos", Nucleosides  and Nucleotides, 1989, (8) 649-657.
  30. Cazenave, C., Stein, C.A., Loreau, N., Thuong, N.T., Neckers, L., Subasinghe, C., Helene, C., Cohen, J. and Toulme, J.-J. "Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides",  Nucl. Acids Res., 1989, (17) 4255-4273.
  31. Stein, C.A., Matsukura, M., Subasinghe, C., Broder, S., and Cohen, J.  "Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of  de novo  infection by HIV",  AIDS Res. and Human Retroviruses, 1989, (5) 639-646.
  32. Mori, K., Boiziau, C., Cazenave, C.,  Matsukura, M., Subasinghe, C., Cohen, J.  Broder, S., Toulme, J.-J., and Stein, C.A. "Phosphoroselenoate oligodeoxynucleotides:  Synthesis, physico-chemical characterization, anti-sense inhibitory properties and anti-HIV activity"  Nucl. Acids Res., 1989, (17) 8207-8219.
  33. Gazdar, A.F., Oie, H., Shackleton, C., Chen, T., Triche, T., Myers, C., Chrousos, G., Brennan, M., Stein, C.A. and LaRocca, R. "Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis", Cancer Res., 1990, (50) 5488-5496.
  34. LaRocca, R., Meer, J., Gilliatt, R., Stein, C.A., Cassidy, J., Myers, C.E., and Dalakas, M., "Suramin-induced polyneuropathy", Neurology, 1990 (40) 954-960.
  35. Gao, W., Hanes, R., Vazquez-Padua, M., Stein, C.A., Cohen, J., and Cheng, Y.-C. "Inhibition of herpes simplex virus type 2 growth by phosphorothioate oligodeoxynucleotides,"  Antimicrobial Agents Chemother., 1990 (34), 808-812.
  36. LaRocca, R., Stein, C.A., Danesi, R., Jamis-Dow, C.A., Weiss, G.H., and Myers, C. "Suramin in adrenal cancer: Modulation of steroid hormone production, cytotoxicity in vitro  and clinical antitumor effect."  J. Clin. Endocrinol. Metabolism, 1990 (71) 497-504.
  37. Stein, C.A., Iversen, P.L., Subasinghe, C., Cohen, J., Stec, W.J., and Zon, G. "Preparation of 35S-labeled polyphosphorothioate oligodeoxynucleotides by use of hydrogen phosphonate chemistry," Analytical Biochemistry, 1990 (188) 11-16.
  38. Reed, J.C., Stein, C.A., Subasinghe, C., Haldar, S., Croce, C.M., Yum, S., and Cohen, J. "Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides," Cancer Res., 1990 (50) 6565-6570.
  39. Stein, C.A., Neckers, L.M., Nair, B.C., Mumbauer, S., Hoke, G., and Pal, R. "Phosphorothioate oligodeoxynucleotide interferes with binding of HIV-1 gp120 to CD4", J. Acquired Immune Deficiency Syndromes, 1991, (4) 686-693.
  40. La Rocca, R.V., Stein, C.A., Danesi, R., Cooper, M.R., Uhrich, M., and Myers, C.E. "A pilot study of suramin in the treatment of metastatic renal cell carcinoma," Cancer, 1991, (67) 1509-1513.
  41. Stein, C.A., Pal, R., DeVico, A.L., Hoke, G., Mumbauer, S., Kinstler, O., Sarngadharan, M.G., and Letsinger, R.L.  "Mode of action of 5'-linked cholesteryl phosphorothioate oligodeoxynucleotides in inhibiting syncytia formation and infection by HIV-1 and HIV-2 in vitro", Biochemistry, 1991 (30) 2439-2444.
  42. Nakajima, M., DeChavigny, A., Johnson, C.E., Hamada, J., Stein, C.A., and Nicolson, G.L. "Suramin:  A potent inhibitor of melanoma heparanase and invasion", J. Biol. Chem., 1991 (266) 9661-9666.
  43. Chou, T.-C., Zhu, Q.-Y., and Stein, C.A. "Differential alteration of the anti-HIV-1 effect of phosphorothioate oligodeoxynucleotide S-dC28 by AZT, interferon-alpha, and dextran sulfate", AIDS Research Human Retrovir., 1991, (7) 943-951.
  44. Pal, R., Mumbauer, S., Hoke, G., LaRocca, R., Myers, C., Sarngadharan, M.G., and Stein, C.A.  "Effect of Evans Blue and Trypan Blue on Syncytia Formation and Infectivity of Human Immunodeficiency Virus Type I and Type II In Vitro", AIDS Research Human Retrovir., 1991, (7) 537-543.
  45. Myers, C., Cooper, M., Stein, C.A, LaRocca, R., Walther, M.M., Weiss, G., Choyke, P., Dawson, N., Steinberg, S., Uhrich, M.M., Cassidy, J., Kohler, D.R., Trepel, J., and Linehan, W.M. "Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer", J. Clin. Oncology, 1992, (10) 881-889.   (See accompanying editorial "Suramin awakes?").
  46. Marshall, W.S., Beaton, G., Stein, C.A., Matsukura, M., and Caruthers, M.H. "Inhibition of human immunodeficiency virus activity by phosphorodithioate oligodeoxycytidine",  Proc. Natl. Acad. Sci., 1992, (89) 6265-6269.
  47. Wade, T., Kasid, A., Stein, C.A., LaRocca, R.V., Sargent, E.R., Gomella, L., Myers, C., and Linehan, W. M. "Suramin interference with transforming growth factor-b inhibition of human renal cell carcinoma in culture", J. Surg. Res., 1992 (53)195-198.
  48. LaRocca, R.V., Cooper, M.R., Stein, C.A., Kohler, D., Uhrich, M., Weinberger, E. and Myers, C.E.  "A pilot study of suramin in the treatment of progressive refractory follicular lymphomas", Ann. Oncology, 1992, (3), 571-573.
  49. Saxon, M., Schieren, I., Zhang, L.-M., Tonkinson, J.L., and Stein, C.A.  "Stimulation of calcium influx in HL60 cells by cholesteryl-modified homopolymer oligodeoxynucleotides",  Antisense Res. Devel., 1992, (2) 243-250.
  50. Yakubov, L.A., Vlassov, V.V., Zhang, L.-M. and Stein, C.A. "Interaction of oligonucleotides with a recombinant CD4 Receptor,"  Doklady Akademii Nauk Rossiya, 1992 (327) 593-597
  51. Krieg, A.M., Tonkinson, J., Matson, S., Zhao, Q., Saxon, M., Zhang, L.-M., Bhanja, U., Yakubov, L. and Stein, C.A. "Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy,"  Proc. Natl. Acad. Sci. USA, 1993, (90), 1048-1052.
  52. Stein, C.A., Tonkinson, J.L., Zhang, L.-M., Yakubov, L. Gervasoni, J., Taub, R., and Rotenberg, S.A.  "Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells," Biochemistry, 1993, (32), 4855-4861.
  53. Stein, C.A., Cleary, A.M., Yakubov, L., and Lederman, S. "Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus Type 1 gp120", Antisense Res. Devel., 1993, (3) 19-31.
  54. Yakubov, L., Khaled, Z., Zhang, L.-M., Truneh, A., Vlassov, V., and Stein, C.A.  "Oligodeoxynucleotides interact with recombinant CD4 at multiple sites", J. Biol. Chem., 1993, (268), 18818-18823.
  55. Perez, J.R., Li, Y., Stein, C.A., Majumder, S., van Oorschot, A., and Narayanan, R. "Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides",  Proc. Natl. Acad. Sci. USA, 1994, (91) 5957-5961.
  56. Archambault, D., Stein, C.A., and Cohen, J.S.  "Phosphorothioate oligonucleotides inhibit the replication of lentiviruses and type D retroviruses, but not that of type C retroviruses", Archives Virol., 1994, (139) 97-109.
  57. Tonkinson, J.L., and Stein, C.A. "Patterns of intracellular compartmentalization, trafficking and acidification of 5'-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells",  Nucl. Acids Res., 1994, (22) 4268-4275.
  58. Tonkinson, J.L., Guvakova, M., Khaled, Z., Lee, J., Yakubov, L., Marshall, W.S., Caruthers, M.H., and Stein, C.A. "Cellular pharmacology and protein binding of phosphoromonothioate and phosphorodithioate oligodeoxynucleotides: A comparative study",  Antisense Res. Devel., 1994, (4) 269-278.
  59. LaRocca, R., Cooper, M., Danesi, R., Stein, C.A., and Myers, C.E. "Suramin therapy for malignant thymoma:  A case report",  European J. Cancer 1994, (30) 718-719.
  60. Khaled, Z., Rideout, D., O'Driscoll, K.R., Petrylak, D., Cacace, A., Patel, R., Chiang, L., Rotenberg, S., and Stein, C. A.  "Effects of suramin-related and other clinically therapeutic polyanions on protein kinase C activity",  Clin. Cancer Res., 1995, (1) 113-122.
  61. Stein, C.A., Khan, T., Khaled, Z., and Tonkinson, J. "Cell surface binding and cellular internalization properties of suramin, a novel antineoplastic agent", Clin. Cancer Res., 1995, (1) 509-517.
  62. Guvakova, M.A., Yakubov, L.A., Vlodavsky, I., Tonkinson, J.L., and Stein, C.A. "Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix",  J. Biol. Chem., 1995, (270) 2620-2627.
  63. Su, Z.-Z., Yemul, S., Stein, C.A., and Fischer, P. "c-fos is a positive regulator of carcinogen enhancement of adenovirus transformation",  Oncogene, 1995, (10) 2037-2049.
  64. Henderson, G. B., and Stein, C.A. "5'-Cholesteryl phosphorothioate oligodeoxynucleotides: Potent inhibition of methotrexate transport and antagonism of methotrexate toxicity in cells containing the reduced-folate carrier",  Nucl. Acids Res., 1995, (23) 3726-3731.
  65. Bishop, W., Lin, J., Wen, J., Stein, C.A., and Krieg, A. "Interruption of a TGF-a-EGF receptor autocrine loop in Caco-2 cells by TGF-a antisense oligodeoxynucleotides", Gastroenterology, 1995, (109) 1882-1889.
  66. Sharma, H., Sokoloski, J., Sartorelli, A., Stein, C.A., Nichols, G., Khaled, Z., Ratan, R., Perez, J., Maltese, J., Telang, N., and Narayanan, R.  "Differentiation of immortal cells inhibits telomerase activity: Implications in cancer", Proc. Natl. Acad. Sci. USA, 1995, (92) 12343-12346.
  67. Benimetskaya, L., Tonkinson, J., Koziolkiewicz, M., Karwowski, B., Guga, P., Zeltser, R., Stec, W., and Stein, C.A.  "Binding of phosphorothioate oligodeoxynucleoides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent", Nucl. Acids Res., 1995, (23) 4239-4245.
  68. Khaled, Z., Benimetskaya, L., Khan, T., Zeltzer, R., Sharma, H., Narayanan, R., and Stein, C.A. "Multiple mechanisms may contribute to the cellular antiadhesive effects of phosphorothioate oligodeoxynucleotides", Nucl. Acids Res., 1996, (24) 737-745.
  69. Wang, W., Chen, H., Schwartz, A., Stein, C.A. and Rabbani, L.  "Sequence-independent inhibition of in vitro vascular smooth muscle proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides", J. Clin. Invest., 1996, (98) 443-450.
  70. Lederman, S., Sullivan, G., Benimetskaya, L., Lowy, I., Land, K., Khaled, Z., Cleary, A., Yakubov, L., and Stein, C.A.  "Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independently of G-tetrad formation", Antisense Nucleic Acid Drug Devel. (formerly Antisense Research and Development), 1996, (6) 281-289.
  71. Wang, W., Chen, H., Warshofsky, M., Schwartz, A., Stein, C.A., and Rabbani, L.  "Phosphorothioate oligodeoxynucleotide sequence-independent inhibition of vascular smooth muscle cell adhesion and fibrinolysis", Antisense Nucleic Acid Drug Devel. 1997, (7) 101-108.
  72. Benimetskaya, L., Loike, J., Khaled, Z., Loike, G., Silverstein, S., Cao, L., El-Khoury, J., Kai, T.-Q., and Stein, C.A. "Mac-1 (CD11b/CD18) is a cell surface oligodeoyxnucleotide binding protein", Nature-Medicine, 1997, (3) 414-420.
  73. Rockwell, P., O'Connor, W., King, K., Goldstein, N., Zhang, L.M. and Stein, C.A. "Cell surface perturbations of the EGF and VEGF receptors by phosphorothioate oligodeoxynucleotides", Proc. Natl. Acad. Sci. USA, 1997, (94) 6523-6528.
  74. Liu, C.-Y., and Stein C.A. "Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression", Clin. Cancer Res., 1997, (3) 2039-2046.
  75. Benimetskaya, L., Berton, M., Kolbanovsky, A., Benimetsky, S. and Stein, C.A. "Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (p65) "antisense" oligodeoxynucleotide", Nucl. Acids Res., 1997, (25) 2648-2656.
  76. Wang, W., Chen, H., Schwartz, A., Cannon, P., Stein, C.A., and Rabbani, L. "Chain-length dependency, time course, and distribution of the non-sequence-specific effects of phosphorothioate oligodeoxynucleotides on in vivo neointimal formation", Antisense Nucl. Acid Drug Devel., 1997, (7) 559-566.
  77. Liu, C.-Y., Rubin, M., Omene, C., Lederman, S., and Stein, C.A. "Prostate cancer cells constitutively secrete Fas Ligand in vitro", Clin. Cancer Res. 1998, (4) 1803-1811.
  78. Wang, W., Chen, H., Sun, J., Benimetskaya, L., Schwartz, A., Cannon, P., Stein, C.A., and Rabbani, L.  "A comparison of guanosine-quartet inhibitory effects versus cytidine homopolymer inhibitory effects on rat neointimal formation", Antisense Nucl. Acid Drug Devel. 1998, (8) 227-236.
  79. Yakubov, L., Kit, Y., Richter, V., Andreeva, A., Karamyshev, V., Stein, C.A., and Vlassov, V.  "The extracellular domain of the CD4 receptor is a protein kinase", FEBS Lett., 1998 (431) 45-48.
  80. Benimetskaya, L., Takle, G., Vilenchik, M., Lebedeva, I., Miller, P., and Stein, C.A.  "Cellular delivery of antisense oligodeoxynucleotides by a novel cationic porphyrin vehicle", Nucl. Acids Res., 1998, (26) 5310-5317.
  81. Berton, M., Benimetskaya, L., Weil, R., Zwillenberg, L., Stein, C.A., and Gurny, R.  "Uptake of oligonucleotide loaded nanoparticles in prostatic cancer cells and their intracellular localization", Euro. J. Pharmaceutics Biopharmaceutics, 1999, (47) 119-123.
  82. Berton, M., Alleman, E., Stein, C.A., and Gurny, R.  “Highly loaded nanoparticulate carrier using an hydrophobized antisense oligonucleotide complex", Euro. J. Pharmaceutical Sciences, 1999, (9)163-170
  83. Khaled, Z., Ho, Y., Benimetskaya, L., Deckelbaum, R. and Stein, C.A. “w-6 Polyunsaturated fatty acid stimulated cellular internalization of phosphorothioate oligodeoxynucleotides: Evidence for protein kinase C-z dependency", Biochem. Pharmacol. 1999, (58) 411-423.
  84. Yamamoto, H., Soh, J.-W., Klein, M., Zhang, L.-M., Schieren, I., Stein, C.A., and Weinstein, I.B.  "Antisense to Rb inhibits growth and induces apoptosis in a colon carcinoma line", Clin. Cancer Res., 1999, (5) 1805-1815.
  85. Simon, A., Giedd, K., Schwartz, A., Wang, W., Sun, J., Marboe, C., Stein, C.A., and Rabbani, L.  “Porous balloon delivery of SdC28 does not prevent restenosis in the porcine coronary artery model of balloon injury”, Antisense Nucleic Acid Drug Devel., 1999, (9) 549-553.
  86. Miao, H., Elkin, M., Aingorn, E., Ishai-Michaeli, R., Stein, C.A., and Vlodavsky, I.  “Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides”, Int. J. Cancer 1999,  (83) 424-31
  87. Ma, M., Benimetskaya, L., Lebedeva, I., Dignam, J., Takle, G., and Stein, C.A. “Intracellular mRNA cleavage induced via activation of RNase P by nuclease-resistant external guide sequences (EGS)”, Nature-Biotechnol.,  2000, (18) 58-61.
  88. Lebedeva, I., Rando, R., Ojwang, J., Cossum, P., and Stein, C.A.  “Bcl-xL in prostate cancer cells:  Effects of overexpression and downregulation on chemosensitivity”  Cancer Res., 2000, (60) 6052-6060.
  89. Vilenchik, M., Benimetsky, L., Miller, P., and Stein, C.A. “Evidence for higher order structure formation by the c-myb 18-mer phosphorothioate antisense (codons 2-7) oligodeoxynucleotide: Potential relationship to antisense c-myb inhibition”, Antisense Nucleic Acid Drug Devel., 2001, (11) 87-97.
  90. Koziolkiewicz, M., Gendaszewska, M., Maszewska, M., Stein, C.A. and Stec, W. J.  “The mononucleotide-dependent, non-antisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends on the activity of an ecto-5’-nucleotidase”, Blood, 2001, (98) 995-1002.
  91. Su, Z-z., Lebedeva, I., Stein, C.A., Reed, J.C., Dent, P., and Fisher, P.B.  A combinatorial approach for selectively inducing programmed cell death in human pancreatic cells”, Proc. Natl. Acad. Sci USA, 2001, (98) 10332-10337
  92. Lebedeva, I., Rando, R., Ojwang, J., Cossum, P., and Stein, C.A.  “Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides”, J. Urology, 2001 (166) 461-469.
  93. Berton, M., Turelli, P., Trono, D., Stein, C.A., and Gurny, R.  “Inhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticles”, Pharmaceutical Res., 2001, (18) 1096-1101.
  94. Benimetskaya, L., Miller, P., Benimetsky, S., Stec, W., Guga P., Beaucage, S., Halperin, A., and Stein, C.A. “Inhibition of potentially anti-apoptotic proteins by antisense PKC-a (Isis 3521) and antisense Bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: Relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells”, Mol. Pharmacol., 2001, (60) 1296-1307.
  95. Benimetskaya, L., Guzzo-Pernell, N., Ting, S., Lai, J., Miller, P., and Stein, C.A. “Protamine-fragment peptides linked to an SV40 nuclear localization signal deliver oligonucleotides that produce antisense effects in prostate and bladder carcinoma cells”, Bioconjugate Chem., 2002, (13) 177-187.
  96. Vilenchik, M., Raffo, A., Benimetskaya, L., Shames, D., and Stein, C.A. “Antisense RNA downregulation of bcl-xL expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents”, Cancer Res., 2002, (62) 2175-2183.
  97. Roberts, K.E., Hamale-Bena, D., Stein, C.A., and Cole, R. “Pulmonary Tumor Embolism: A case and review of the literature”, Amer. J. Med., 2003, (115) 228-232.
  98. Lai, J., Benimetskaya, L., Santella, R., Wang, Q., Miller, P. and Stein, C.A. “G3139 (Oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent , non-antisense manner”, Molecular Cancer Therap.,  2003, (2) 1031-1043
  99. Lebedeva, I., Sarkar, D., Su, Z., Kitada, S., Dent, P., Stein, C.A., Reed, J., and Fisher, P. “Bcl-2 and bcl-xL differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL24”, Oncogene, 2003, (22) 8758-8773.
  100. Raffo, A., Lai, J., Miller, P., Stein, C.A., and Benimetskaya, L. “Antisense RNA downregulation of Bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen)”,  Clin. Cancer Res., 2004, (10) 3195-3206.
  101. Benimetskaya, L., Wittenberger, T., Stein, C.A., Hofmann, H.-P., Weller, C., Lai,  J., Miller, P.,  and Gekeler, V. “Changes in gene expression induced by G3139 in prostate carcinoma cells are recapitulated at least in part by treatment with interferon-b and -g”, Clin. Cancer Res., 2004, (10) 3678-3688. 
  102. Benimetskaya, L., Lai, J., Wu, S., Hua, E., Khvorova, A., Miller, P. and Stein, C.A. “Relative Bcl-2 independence of drug induced cytotoxicity and resistance in 518A2 melanoma cells”, Clin. Cancer Res., 2004, (10) 8371-8379. 
  103. Lai, J., Benimetskaya, L., Khvorova, A., Wu, S., Hua, E., Miller, P., and Stein, C.A. “Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells ”, Molecular Cancer Therap. 2005, (4) 305-315.
  104. Benimetskaya, L., Miller, P., and Stein, C.A. “518A2 melanoma cells are protected by G3139 and other anti-neoplastic agents against the cytotoxic effects of DTIC”, Oligonucleotides, 2005, (15) 206-214.
  105. Anderson, E., Miller, P., Ilsley, D., Marshall, W., Khvorova, A., Stein, C.A., and Benimetskaya, L.,  “Gene profiling study of G3139 and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature”, Cancer Gene Therapy, 2006, (13) 406-414.
  106. Gekeler, V., Gimmnich, P, Hofmann, H.-P., Grebe, C., Romele, M., Leja, A., Baudler, M., Benimetskaya, L., Gonser, B., Pieles, W., Maier, T., Wagner, T., Sanders, K., Beck, J., Hanauer, G., and Stein, C.A., “G3139 and other CpG-containing immuno-stimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice,” Oligonucleotides, 2006, (16) 83-93.
  107. Lai, J., Tan, W., Benimetskaya, L., Miller, P., Colombini, M., and Stein, C.A. “A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC”, Proc. Natl. Acad. Sci. USA, 2006, (103) 7494-7499. 
  108. Benimetskaya, L., Ayyanar, K., Kornblum, N., Castanotto, D., Rossi, J., Wu, S., Lai, J., Popova, N., Brown, B., Miller, P., McMicken, H., Chen, Y., and Stein, C.A. “Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro”, Clin. Cancer Res., 2006, (12) 4940-4948. 
  109. Tan, W., Lai, J., Miller, P., Stein, C.A., and Colombini, M. “G3139 reduces mitochondrial outer membrane permeability to ADP”, Amer. J. Physiol. Cell Physiol., 2007, (292) C1388-C1397.
  110. Lai, J., Brown, B., Voskresenskiy, A., Vonhoff, S., Tan W., Colombini, M., Weeratna, R., Miller, P., Benimetskaya, L., and Stein, C.A. “Comparison of D-G3139 and its enantiomer L-G3139 in melanoma cells demonstrates minimal in vitro but dramatic in vivo chiral dependency”, Molecular Therapy, 2007, (15) 270-278.
  111. Zhao, H., Peng, P., Yu, D., Longley, C., Zhang, Y., Borowski, V., Mehlig, M., Reddy, P. Xia, J., Borchard, G., Lipman, J., Benimetskaya, L., and Stein, C.A. “Delivery of G3139 using releasable PEG-linkers: Impact on pharmacokinetic profile and anti-tumor efficacy”, J. Controlled Release, 2007, (119) 143-152.       
  112. Stein, C.A., Goel, S. and Ghavamian, R. “Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer treated with ketoconazole on concurrent lovastatin therapy”, Invest. New Drugs, 2007, (25) 277-278.
  113. Tan, W., Loke, Y.-H., Stein, C.A., Miller, P. and Colombini, M.  “Phosphorothioate oligonucleotides block the VDAC channel”, Biophys. J., 2007 (93) 1184-1191.
  114. Benimetskaya, L., Wu, S., Voskresenskiy, A., Echart, C., Zhou, J.-F., Shin, J., Iacobelli, M., Richardson, P., Ayyanar, K., and Stein, C.A. “Angiogenesis-alteration by Defibrotide: Implications for its mechanism of action in severe hepatic veno-occlusive disease”, Blood,  2008, (112) 4343-4352.
    See comment: Lazarus, H, and McCrae, K. “SOS! Defibrotide to the rescue”  Blood, 2008, (112) 3924-3925.
  115. Stein, C.A., Wu, S., Voskresenskiy, A., Zhou, J.-F., Shin, J., Miller, P., and Benimetskaya, L.  “G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in-vitro endothelial cell growth and tubular morphogenesis”, Clinical Cancer Res., 2009, (15) 2797-2807.
  116. Stein, C.A., Hansen, B., Lai, J., Soifer, H., Wu, S., Voskresenskiy, A., Hoeg, A., Worm, J., Hedtjarn, M., Soulemanian, N., Miller, P., Castanotto, D., Benimetskaya, L., Oerum, H., and Koch, T. “Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents”, Nucleic Acids Res. 2009 doi:10.1093/nar/gkp841.
  117. Agarwala, S., Keilholz, U., Gilles, E., Bedikian, A., Wu, J., Kay, R., Stein, C.A., Itri, L., Suciu, S., and Eggermont, A. “LDH correlation with survival in advanced melanoma from two large, randomized trials: Oblimersen (GM301) and EORTC18951”, Eur. J. Cancer, 2009, (45) 1807-1814.
  118. Michaelson, M.D., Bellmunt, J., Hudes, G., Goel, S., Lee, R., Kantoff, P., Stein, C.A., Lardelli, P., Pardos, I., Kahatt, C., Nieto, A., Cullell-Young, M., Lewis, N., Smith, M.  Multicenter phase II trial of trabectin in patients with metastatic castration resistant prostate cancer, Annals of Oncology, 2011, doi:10.1093/annonc/mdr399
  119. Soifer, H., Souleimanian, N., Wang, S., Voskresenskiy, A., Collak, F., Cinar, B., and Stein, C.A.  “Direct regulation of androgen receptor activity in prostate cancer cells by potent CYP17 inhibitors”, J. Biol. Chem., 2012, (287), 3777-3787.
  120. Soulemanian, N.,  Deleavy, G., Soifer, H., Wang, S., Damha, M., Tiemann, K., and Stein, C.A. “Antisense 2’-fluoro, 2’-deoxyarabino nucleic acids (2’F-ANA) oligonucleotides:  In vitro gymnotic silencers of gene expression whose potency is enhanced by fatty acids”,  Molecular Therapy-Nucleic Acids, 2012, 1, e43; doi10.1038/mtna.2012.35.
  121. Pal, S., Twardowski, P., and Stein, C.A.  “Long-term treatment of an octogenarian with castrate resistant prostate cancer (CRPC) with cabazitaxel”, Clinical Genitourinary Cancer, 2012, (10), 274-276 2012
  122. Pal, S., Yamzon, J., Sun, V., Carmichael, C., Saikia, J., Ferrell, B., Frankel, P., Yamzon, J., Twardowski, P., Stein, C.A., Margolin, K. “Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor:  Clinical outcome and quality of life in long-term survivors,” Clinical Genitourinary Cancer, 2013, (11) 121-127. 
  123. Bhagat, T., Zhou, L., Sokol, L., Gundabolu, K., Gordon, S., Mantzaris, I, Gligich, O., Yu, Y., Nischal, S., Bhattacharyya, S., Polineni, J., Chrysofakis, G., Schinke, C., Bhatia, K., Wickrema, A., Pellagatti, A., Boultwood, J., Kambhampati, S., Parekh, S., Steidl, U., Stein, C., Ju, W., Liu, G., List, A., Bitzer, M., and Verma, A.  miR-21 mediates hematopoietic suppression in MDS by activating TGF-b signaling, Blood, 2013 (121), 2875-2881.
  124. Williams, S., Atalla, C., Ghavamian, R., Stein, C.A., Hoenig, D.  “‘Extreme’ renal preservation:  Neoadjuvant chemotherapy and percutaneous resection for upper tract urothelial carcinoma in a patient with solitary kidney—a case report,” J Endourology, 2013 (27), 427-431.
  125. Rodrigueza, R., Woolliscroft, M., Abdul-Shukkur, E., Forgey, R., McGovren, P., Endert, G., Wagner, A., Holewa, D., Aboukameel, A., Gill, R., Bisgaier, C., Messmann, R., Izbicka, E., Streeper, R. Wick, M., Stiegler, G., Stein, C.A., Monsma, D., Webb, C., Sooch, M., Panzner, S., Mohammed, R., Goodwin, N., Al-Katib, A.  “Development and antitumor activity of a Bcl-2 targeted single-stranded DNA oligonucleotide”, Cancer Chemotherapy and Pharmacology, in press, 2014 
  126. Pal, S., Gartrell, B., Olsson, C., Stein, C.A. “Metastatic adrenocortical carcinoma with a prolonged response to mitotane,” Oncology, July, 2014, 624-625
  127. Castanotto, D., Lin, M., Kowolik, C., Wang, L., Ren, X.-Q., Soifer, H.S., Koch,T., Hansen, B.R., Armstrong, B., Wang, Z., Bauer, P., Rossi, J., and Stein, C.A. “A novel cytoplasmic pathway for antisense-mediated gene silencing in mammalian cells,” submitted.
  128. He, M., Tew, B., Stein, C., Rideout, D., Pal, S., and Jones, J.O. “A synthetic chemical approach to improve the understanding of the multiple activities of abiraterone,” submitted.
  129. Castanotto, D., Lin, M., Nam, S., Horne, D., Stein, C.A.  “The penetration of anti-mir and antisense oligonucleotides into human tumor microspheroids is augmented by inhibitors of c-abl kinase and GSK-3b,” in preparation.

Book Chapters, Reviews And Editorials

  1. Mertelsmann, R., Welte, K., Sykora, K.-W., Kolitz, J., Halloway, K., Fiedler, W., Miller, G., Merluzzi, V., Venuta, S., Engert, A., Stein, C., Polivka, A. and Levi, E. "Treatment of Cancer with Interleukin 2", in Development, Evaluation and Applications of Biologically Active Substances in Cancer Therapy, P. Schuff-Werner and K. Pfitzenmaier, eds., W. Zuckschwerdt Verlag, Munich, 1985,  p. 137-157.
  2. Stein, C.A., and Cohen, J., "Oligodeoxynucleotides as inhibitors of gene expression: A review", Cancer Research, 1988, (48), 2659-2668.
  3. Stein, C.A. and Cohen, J. "Antisense Compounds: Potential role in cancer therapy", in DeVita, V., et al., eds. "Important Advances in Oncology-1989" J.B. Lippincott, New York, 1989, p. 79-97.
  4. Stein, C.A., and Cohen, J.S. "Phosphorothioate oligodeoxynucleotide analogues", in "Oligodeoxynucleotides: Anti-sense Inhibitors of Gene Expression," J. Cohen, ed.  McMillen Press, London, 1989, p 97-118.
  5. Stein, C.A., LaRocca, R.V., and Myers, C.E.  "Suramin:  An old compound with new biology" in Principles and Practice of Oncology Updates, Number 5, V. Devita, et al., eds. J.B. Lippincott, New York, 1990, p. 419-431.
  6. LaRocca, R.V., Stein, C.A., and Myers, C.E. "Suramin-prototype of a new generation of antitumor compounds."  Cancer Cells, 1990, (2), 106-115.
  7. LaRocca, R., Stein, C.A., Danesi, R., and Myers, C. "Suramin, a novel antitumor compound", J. Steroid Biochem. Molecular Biol., 1990, (37), 893-899.
  8. Myers, C.E., LaRocca, R.V., Cooper, M.R., Danesi, R., Jamis-Dow, C.A., Stein, C.A., and Linehan, W.M. "Role of suramin in cancer biology and treatment", in Molecular Foundations of Oncology, S. Broder, ed., J. Wiley, Baltimore, 1991, pp 419-431.
  9. Stein, C.A., Tonkinson, J.L., and Yakubov, L. "Phosphorothioate oligodeoxynucleotides -- Anti-sense inhibitors of gene expression?" Pharmacology and Therapeutics, 1991, (52), 365-384.
  10. Stein, C.A. "Antisense oligodeoxynucleotides -- Promises and pitfalls", Leukemia, 1992, (6), 967-974.
  11. Stein, C.A. and Pal, R. "Anti-HIV compounds with membrane oriented specificity - early results" in Cellular Membrane: A Key to Disease Processes, C. Onishi and S. Onishi, eds., CRC Press, Boca Raton, FL, 1992, Chapter 14, pp. 337-353.
  12. Stein, C.A. "Antisense inhibition of gene expression", in Principles and Practice of Oncology, 4th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 1993, 2646-2655.
  13. Stein, C.A.  "Suramin: A novel antineoplastic agent with multiple potential mechanisms of action", Cancer Research, 1993, (52), 2239-2248.
  14. Stein, C.A. and Cheng, Y.-C.  "Antisense oligonucleotides: Is the bullet really magical?", Science, 1993, (261) 1004-1012.
  15. Tonkinson, J., and Stein, C.A. "Antisense nucleic acids -- prospects for antiviral intervention", Antiviral Chemistry and Chemotherapy, 1993, (4), 193-200.
  16. Tonkinson, J., and Stein, C.A. "The cellular internalization of antisense oligodeoxynucleotides", Antiviral News, 1993, (1), 39-40.
  17. Rideout, D., and Stein, C.A. "Suramin and its analogs as antineoplastic agents", Drugs of the Future, 1994, (19), 161-174.
  18. Stein, C.A. and Narayanan, R. "Antisense oligonucleotides", Current Opinion in Oncology, 1994, (6), 587-594.
  19. Stein, C.A. and Krieg, A.  Editorial  - "Problems in interpretation of data derived from in vitro  and in vivo  use of antisense oligodeoxynucleotides" Antisense Research and Development, 1994, (4), 67-69.
  20. Stein, C.A. "Antisense oligodeoxynucleotides" in Biologic Therapy of Cancer, 2nd ed., V. DeVita, et al., eds. J.B. Lippincott, New York, 1995, 759-773.
  21. Stein, C.A. "Does antisense exist?” Commentary in Nature-Medicine, 1995, (1), 1119-1121.  See letter to the editor and response in Nature-Medicine, 1996, (2), 131-132.
  22. Tonkinson, J., and Stein, C.A. "Antisense oligonucleotides-The potential for clinical application", Cancer Investigation, 1996, (14), 54-65.
  23. Stein, C.A. and Narayanan, R. "Cellular Biochemistry of Oligodeoxynucleotides",  in Perspectives in Drug Discovery and Design, P. Anderson et al., eds., 1996, (4), 1-10.
  24. Gewirtz, A., Stein, C.A. and Glazer, P.  "Facilitating Oligonucleotide Delivery: Helping Antisense Deliver On Its Promise", Commentary, Proc. Natl. Acad. Sci. USA, 1996, (93), 3161-3163.
  25. Stein, C.A.  "Phosphorothioate Oligodeoxynucleotides-A Question of Specificity" Trends in Biotechnology, 1996, (14), 147-149.
  26. Stein, C.A. and Cheng, Y.-C.  "Antisense Inhibition of Gene Expression", in Principles and Practice of Oncology, 5th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 1997, 3059-3074
  27. Stein, C.A. "Antisense c-myc Phosphorothioate Oligodeoxynucleotides-A Question of Mechanism", invited editorial, J. Natl. Cancer Inst., 1996, (88), 391-393.
  28. Stein, C.A. "Exploiting the Potential of Antisense: Beyond Phosphorothioate Oligodeoxynucleotides", Chemistry and Biology, 1996, (3), 319-323.
  29. Stein, C.A.  "Controversies in the Cellular Pharmacology of Oligodeoxynucleotides," Antisense and Nucl. Acid Drug Devel., 1997, (7), 207-210
  30. Stein, C.A. and Krieg, A. "Non-sequence specific effects of phosphorothioate oligodeoxynucleotides. In Antisense Technology: A Practical Approach, C. Lichtenstein and W. Nellen, eds. Oxford University Press, Oxford, UK, 1997, 241-264.
  31. Stein, C.A. "Mechanisms of Intracellular Oligodeoxynucleotide Internalization", Ciba Foundation Symposium #209, London, UK, 1997, 79-93. 
  32. Stein, C.A. and Krieg, A., Eds.  "Applied Antisense Oligonucleotide Technology", J. Wiley and Sons, Inc., New York, NY, 1998, 540 pp.
  33. Hanss, B., Stein, C.A. and Klotman, P. "Cellular Internalization of Oligodeoxynucleotides", in Stein, C.A. and Krieg, A., eds. "Applied Antisense Oligonucleotide Technology", J. Wiley and Sons, Inc., New York, NY, 1998, 111-128.
  34. Stein, C.A. "How to design an antisense oligodeoxynucleotide experiment:  A consensus approach", Antisense and Nucleic Acid Drug Development, 1998, (8), 129-132.
  35. Lebedeva, I.. and Stein, C.A.  "Phosphorothioate Oligodeoxynucleotides", in Rabbani, L., ed. "Applications of Antisense Therapies to Restenosis", Volume I of "Antisense Oligodeoxynucleotides", Stein, C.A., series ed.  Kluwer Academic Publishers, Norwell, MA, 1999, 99-118.
  36. Wyatt, J. and Stein, C.A.  "G-quartet Inhibitory Effects of Phosphorothioate Oligodeoxynucleotides", in Rabbani, L., ed. "Applications of Antisense Therapies to Restenosis", Volume I of "Antisense Oligodeoxynucleotides", Stein, C.A., series ed.  Kluwer Academic Publishers, Norwell, MA, 1999, 133-140.
  37. Rabbani, L., and Stein, C.A. "Potential use of oligonucleotides in restenosis," Antisense and Nucleic Acid Drug Development, 1999, (8), 487-492.
  38. Stein, C.A. "In Vitro Delivery of Oligonucleotides and Some Antisense Experimental Do's and Dont's,"  Biochem. Biophys. Acta, 1999, (1489) 45-52.
  39. Takle, G., and Stein, C.A. "Cellular Uptake of Oligodeoxynucleotides" in Pharmaceutical Aspects of Oligonucleotides, 1999, P. Couvreur and C. Malvy, eds. Taylor & Francis, London, UK, p. 201-212. 
  40. Benimetskaya, L., Tonkinson, J., and Stein, C.A. "Determination of Cellular Internalization of Oligonucleotides, in Methods in Enzymology: Antisense Techniques, 1999, M. Ian Phillips, ed., Academic Press, Orlando, p. 287-297.
  41. Stein, C.A.  “Keeping the Biotechnology of Antisense in Context”, Commentary in Nature-Biotechnology, 1999, (17), 209.
  42. Stein, C.A. “Hybridization Prediction Gets to First Base”, Nature-Biotechnology, News and Views, 1999 (17), 751-752.
  43. Stein, C.A. “Molecular and Cellular Mechanisms of Action of Taxanes”, Seminars in Oncology, 1999, (26) 15suppl. 3-7.
  44. Stein, C.A. "Antisense Oligodeoxynucleotides" in Biologic Therapy of Cancer, 3rd ed., S. Rosenberg, ed. J.B. Lippincott, New York, 2000, 812-824.
  45. Lebedeva, I., and Stein, C.A. “Antisense in Cancer: Recent Advances”, BioDrugs, 2000, (13), 195-216.
  46. Stein, C.A.  “Is Irrelevant Cleavage the Price of Antisense Efficacy?”, Pharmacol. Therap., 2000 (85), 231-236.
  47. Lebedeva, I., Benimetskaya, L., Stein, C.A., and Vilenchik, M.  “Delivery of Oligonucleotides to Cells”, European J. of Pharmaceutics and Biopharmaceutics, 2000, (50), 101-119
  48. Stein, C.A.  Invited Book Review:  “Better Than Prozac?  Antisense Technology in the Central Nervous System”, Trends in Pharmacol. Sci., 2000, (21), 230-231
  49. Lebedeva, I. and Stein, C.A. “Antisense Oligonucleotides: Promise and Reality”, Annual Review of Pharmacology and Toxicology, 2001 (41), 403-419
  50. Stein, C.A. and Lebedeva, I. “Antisense to Bcl-2 in Therapy for Cancer”, in Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation, Gerson, S., and Lattime, E., eds. 2001, 313-330
  51. Stein, C.A.  and Lebedeva, I.  “Antisense Downregulation of the Apoptosis-Related Bcl-2 and Bcl-xL Proteins: A New Approach to Cancer Therapy”, J. Molecular Biol. (Russ.), 2001 (34), 875-887.
  52. Stein, C.A.  “Guidelines for the Experimental Use of Antisense Oligonucleotides”, J. Clin. Invest., 2001 (108) 641-644.
  53. Stein, C.A. “Antisense that Comes Naturally”, News and Views in Nature Biotechnology, 2001 (19), 737
  54. Koehn, R., Rossi, J., and Stein, C.A. “In Defense of Antisense”, Letter to the Editor in Science, 2001 (293), 1047-1048.
  55. Dias, N., and Stein, C.A. “The Use of Antisense Oligonucleotides to Validate Gene Function”, Molecular Cancer Therapeutics, 2001 (1), 347-355.
  56. Dias, N., and Stein, C.A. “Update on Antisense Oligonucleotide Therapeutics-bcl-2 and PKC-a”, Eur. J. Pharmaceutics and Biopharmaceutics, 2002 (54), 263-269.
  57. Benimetskaya L., and Stein, C.A. “Antisense Therapy: New Advances” Clinical Prostate Cancer, 2002, (1) 20-30.
  58. Stein, C.A.  “Antisense Technology Becomes Therapeutics” Science and Medicine, 2003, (8) 318-327.
  59. Liu, W., Bulgaru, A., Haigentz, M., Stein, C.A., Perez-Soler, R., and Mani, S.  The bcl- 2-family of protein ligands as cancer drugs:  The next generation of therapuetics.  Curr. Med. Chem.-Anti-Cancer Agents, 2003 (3), 217-223.
  60. Nichols, G. and Stein, C.A. “Modulation of the activity of bcl-2 in Waldenstrom’s Macroglobulinemia using antisense oligonucleotides” Semin. Oncol. 2003, (30) 297-299.
  61. Wang, L., Prakash, R., Stein, C.A., Koehn, R., and Ruffner, D.  “Progress in the Delivery of Therapeutic Oligonucleotides: Organ/cellular Distribution and Targeted Delivery of Oligonucleotides In Vivo”, Antisense and Nucleic Acid Drug Development, 2003, (13) 169-189
  62. Cho-Chung, Y., Gewirtz, A., and Stein, C.A. (eds).  Therapeutic Oligonucleotides.  Ann. NY Acad Sci., 2003 (1002).
  63. Stein, C.A., Dias, N., Benimetskaya, L, Jepsen, J., Lai, J., and Raffo, A. “LY900003 (Isis 3521) and G3139 (Genasense; Oblimersen)-Phosphorothioate Antisense Oligonucleotides with Pleotropic Mechanisms of Action.” Nucleic Acid Therapeutics in Cancer, A. Gewirtz, ed., 2004, 171-191.
  64. Stein, C.A., Mani, S., Benimetskaya, L. “Combinations of Chemotherapy with Antisense Approaches Against bcl-2”, in Combination Cancer Therapy:  Modulators and Potentiators, G., Schwartz, ed., Humana Press, 2005, p. 207-228
  65. Stein, C.A., Benimetskaya, L., and Mani, S. "Antisense Inhibition of Gene Expression", in Principles and Practice of Oncology, 7th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2005, p. 2891-2898. 
  66. Stein, C.A. and Rossi, J. “A Critical Assessment of the Potential of Short Interfering RNA Therapeutics’, Drug Discovery Today: Technologies, 2005, www.drugdiscoverytoday.co; http://www.sciencedirect.com (2) 27-31.
  67. Cho-Chung, Y., Gewirtz, A., and Stein, C.A. (eds).  Therapeutic Oligonucleotides—Transcriptional and Translational Strategies for Silencing Gene Expression.  Ann. NY Acad Sci., 2005 (1058)
  68. Benimetskaya, L., Lai, J., Khvorova, A., Wu, S., Miller, P. and Stein, C.A.  “Induction of Apoptosis by G3139 in Melanoma Cells”, Ann. NY Acad. Sci, 2005 (1058) 235-245.
  69. Stein, C.A., Benimetskaya, L., and Mani, S.  “Antisense Strategies for Oncogene Inactivation”, Semin. Oncol. 2005, (32) 563-572.
  70. Kornblum, N., Ayyanar, K., Benimetskaya, L., Richardson, P., Iacobelli, M., and Stein, C.A. “Defibrotide, a Polydisperse Mixture of Single-Stranded Phosphodiester Oligonucleotides with Life-Saving Activity in Severe Hepatic Veno-Occlusive Disease: Clinical Outcomes and Potential Mechanisms of Action”, Oligonucleotides, 2006 (16), 105-114.
  71. Stein, C.A. “The Genasense ‘Learning Curve’”, Letter to the Editor, Nature Biotechnology, 2007, (25) 972-973.
  72. Stein, C.A.  “Genasense: It Ain’t Over Till the Fat Lady Sings”, Editorial, Oligonucleotides, 2007 (17) 345-348.
  73. Stein, C.A. Kornblum, N., Lai, J., and Benimetskaya, L. “Genasense (G3139): An antisense Bcl-2 oligodeoxyribonucleotide with substantial clinical activity and a complex mechanism of action”.  In Therapeutic Oligonucleotides, J. Kurreck, ed., Biomolecular Science, Royal Society of Chemistry, 2008, p. 23-42 
  74. Stein, C.A., Benimetskaya, L., Kornblum, N., and Mani, S. "Antisense Agents", in Principles and Practice of Oncology, 8th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2008.
  75. Stein, C.A., and Colombini, M.  “Specific VDAC Inhibitors:  Phosphorothioate Oligonucleotides,” J. Bioenerg. Biomemb., 2008, (40), 157-162.
  76. Stein, C.A., Hoehn, B., and Rossi, J.  “Oligonucleotide Therapeutics”. In Principles of Anticancer Drug Development, E. Garrett-Mayer, et al., eds. Springer Press, 2011, p. 565-587.
  77. Stein, C.A., and Soifer, H. "Antisense Inhibition of Gene Expression.”   In Principles and Practice of Oncology, 9th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2011.
  78. Soifer, H., Koch, T., Hansen, B., Hoeg, A., Oerum, H., and Stein, C.A. “Silencing of Gene Expression by Gymnotic Delivery of Antisense Oligonucleotides” in M. Kaufmann and C. Klinger, eds., Functional Genomics:  Methods and Protocols: Methods in Molecular Biology, Springer Press, 2011, (815), 333-346.
  79. Stein, C.A. and Goel, S.  “Therapeutic Oligonucleotides—The Road Not Taken,” invited commentary in Clinical Cancer Research, 2011, (17), 6369-6372.
  80. Twardowski, P. and Stein, C.A. “Beyond the Abstract-Direct regulation of androgen receptor activity in prostate cancer cells by potent CYP17 inhibitors.” UroToday.com, July 2, 2012
  81. Hu, J., Hsu, J., Bergerot, P., Yuh, B., Stein, C.A., Pal, S.  “Preoperative therapy for localized prostate cancer: A comprehensive overview”, Maturitas, 2013, (74), 3-9.
  82. Pal, S., Stein, CA, Sartor, O. “Enzalutamide for the treatment of prostate cancer,” Expert Opinion in Pharmacotherapy, 2013, (14), 679-685.
  83. Eroglu, Z., Stein, C.A., Pal, S.  “Targeting angiopoietin-2 signaling in cancer therapy, Expert Opinion in Investigational Drugs, 2013, (22), 813-825.
  84. Stein, C.A. “Delivery of antisense oligonucleotides to cells:  A consideration of some of the barriers,” Chemistry Today, 2014, (32), 4-7.
  85. Stein, C.A., Castanotto, D., Kowolik, C., and Lin, M.  “Antisense oligonucleotide therapy in cancer,”  Expert Opinion in Medical Oncology, 2014, (26), 584-589
  86. Textbook:  Kurreck, J. and Stein, C.A.  “Molecular Medicine,” J. Wiley and Sons, Berlin, 2015, in preparation.


CY Aaron Stein

Arthur and Rosalie Kaplan Professor and Chair

 

  • : 626 471 3890
  • : 626 471 7322
  • DEPARTMENTDepartment of Medical Oncology and Experimental Therapeutics
    City of Hope Medical Center
  • COUNTRYDuarte, CA